Literature DB >> 6086817

Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate.

S W Gollins, J S Porterfield.   

Abstract

35S-labelled West Nile virus was used in radioactive binding, internalization and degradation studies in the macrophage cell line P388D1 in the absence or presence of various concentrations of antiviral antibody. Proteases were used to help distinguish between intracellular and extracellular (bound) virus. It was found that the enhancement in viral infectivity that occurs in the presence of subneutralizing concentrations of antiviral antibody was caused by (i) increased binding of virus to the cell surface and (ii) a higher specific infectivity of antibody-opsonized virus particles, apparently due to a more efficient internalization process. In contrast, little difference was found in the rate of internalization and intracellular degradation for virus particles that did enter the cells. Lysosomotropic amines were capable of markedly inhibiting viral replication in P388D1 cells at an early stage of infection both in the absence and presence of subneutralizing concentrations of antibody, although antibody-mediated enhancement of viral replication remained.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086817     DOI: 10.1099/0022-1317-65-8-1261

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  46 in total

Review 1.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

2.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 3.  Closing the door on flaviviruses: entry as a target for antiviral drug design.

Authors:  Rushika Perera; Mansoora Khaliq; Richard J Kuhn
Journal:  Antiviral Res       Date:  2008-06-11       Impact factor: 5.970

Review 4.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

5.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 6.  Novel approaches to flavivirus drug discovery.

Authors:  Carolyn Botting; Richard J Kuhn
Journal:  Expert Opin Drug Discov       Date:  2012-03-22       Impact factor: 6.098

7.  Protonation of individual histidine residues is not required for the pH-dependent entry of west nile virus: evaluation of the "histidine switch" hypothesis.

Authors:  Steevenson Nelson; Subhajit Poddar; Tsai-Yu Lin; Theodore C Pierson
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

8.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Authors:  Erin Mehlhop; Steevenson Nelson; Christiane A Jost; Sergey Gorlatov; Syd Johnson; Daved H Fremont; Michael S Diamond; Theodore C Pierson
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

9.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.